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Abstract
Plasmacytoid dendritic cells (pDCs) are a subset of dendritic cells endowed with the capacity of producing large amounts of
IFNa. Here we show that the Leukocyte-Associated Ig-like Receptor-1 (LAIR-1) is abundantly expressed on pDCs (the highest
expression among all leukocytes) and its cross-linking inhibits IFNa production in response to Toll-like receptor ligands.
Remarkably, LAIR-1 expression in pDCs is down-regulated in the presence of interleukin (IL)-3, thus indicating coordinated
functions with NKp44, another pDC inhibitory receptor, which is conversely induced by IL-3. Nevertheless, the expression of
NKp44 in pDCs isolated from secondary lymphoid organs, which is thought to be influenced by IL-3, is not coupled to a
decreased expression of LAIR-1. Interestingly, pDCs isolated from peripheral blood of systemic lupus erithematosus (SLE)
patients express lower levels of LAIR-1 while displaying slight but consistent expression of NKp44, usually undetectable on
pDCs derived from healthy donors. Using sera derived from SLE patients, we show that LAIR-1 and NKp44 display synergistic
inhibitory effects on IFNa production by interleukin IL-3 cultured pDCs stimulated with DNA immunocomplexes. In
conclusion, our results indicate that the inhibitory function of LAIR-1 may play a relevant role in the mechanisms controlling
IFNa production by pDCs both in normal and pathological innate immune responses.
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Introduction
Plasmacytoid dendritic cells (pDCs) constitute a distinct subset
of dendritic cells present in lymphoid and non lymphoid tissues
[1,2] and characterized by the ability of producing large amounts
of interferon (IFN)a upon stimulation by toll-like receptor (TLR)-7
and TLR-9 agonists [3]. Given the significance of type I IFNs in
activating a wide range of cells of the innate and adaptive immune
system [4], IFNa production has to be under tight control in order
to prevent aberrant immune response that could harm the host.
Although pDCs display an array of surface receptors able to
modulate their response [5–9], the molecular mechanisms for the
negative regulation of their activity have not yet been completely
elucidated and some of them in fact exhibit peculiar features. For
instance, IRp60 (CD300a), an inhibitory receptor expressed by
different leukocytes [10], has been shown to play an unpredicted
role when cross-linked on pDCs. Indeed, IRp60 triggering
reduces, as expected, TNFa production but increases IFNa
secretion by pDCs [11]. Another surface receptor, NKp44, is
expressed on a subset of pDCs in tonsils and is inducible on PB
pDCs after in vitro culture with interleukin (IL)-3 [12]. NKp44 has
been originally identified as an NK activating receptor [13,14]
signalling through the ITAM-bearing DAP12 adaptor molecule
[15]. Cross-linking of NKp44 on NK cells is associated with
triggering of NK cell-mediated cytotoxicity. Paradoxically, cross-
linking of NKp44 on pDCs does not trigger their functions but
rather significantly inhibits IFNa production in response to TLR9
agonists, namely cytosine-phosphate-guanosine (CpG) oligonucle-
otides [12].
The expression of Leukocyte-Associated Ig-like Receptor-1
(LAIR-1), another relevant immune inhibitory receptor [16,17],
has not been investigated in pDCs so far. LAIR-1 recognizes a
common collagen motif and contains a single extracellular Ig-like
domain and two cytoplasmic tyrosine-based inhibitory motifs
(ITIMs) that bind to the SH2 domain of phosphatases, leading to
dephosphorylation of different kinases [18]. The inhibitory
potential of LAIR-1 was demonstrated on several leukocyte
subsets: cross-linking of LAIR-1 on human NK cells delivers a
potent inhibitory signal that is capable of inhibiting target cell lysis
mediated by resting and activated NK cells [16–19]. Similarly,
LAIR-1 can inhibit the cytotoxic activity of effector T cells upon
CD3 cross-linking or antigen stimulation [20]; also, LAIR-1 cross-
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primary B cells [21] and inhibits the differentiation of peripheral
blood precursors towards myeloid dendritic cells in vitro [22].
In this study, we show that the expression of LAIR-1 on pDCs is
constitutively higher than on all other blood mononuclear cells
and its cross-linking significantly inhibits IFNa production by
pDCs stimulated with CpG oligonucleotides or DNA immuno-
complexes. Remarkably, pDCs isolated from systemic lupus
erithematosus (SLE) patients express lower levels of LAIR-1.
Our data also suggest that this receptor displays coordinated
regulatory functions in concert with NKp44 in order to restrain
IFNa production by pDCs.
Results
LAIR-1 expression in plasmacytoid dendritic cells
Although LAIR-1 has been described in several immune cells,
including subsets of myeloid dendritic cells, its expression has
never been investigated in pDCs. Therefore, we first analyzed
pDCs isolated from peripheral blood and found that LAIR-1 is
constitutively highly expressed on circulating pDCs. Noteworthy,
the expression of LAIR-1 in pDCs was consistently higher than on
all other peripheral blood mononuclear cells (Figure 1A). Cultur-
ing pDCs in the presence of IL-3 resulted in down-regulation of
LAIR-1 expression (Figure 1B,C,D). Similar down-regulation of
LAIR-1 expression was observed on pDCs cultured either in the
presence of TLR ligands or exogenous IFNa (Figure 1C) and the
association of IL-3 with these latter stimuli did not further
contribute to LAIR-1 down-regulation. As shown in figure 1D
(right panel) after 48 h culture in the presence of IL-3, LAIR-1
mRNA was barely detectable.
Interestingly, LAIR-1 down-regulation in the presence of IL-3 is
in sharp contrast with the expression of NKp44, another pDC
inhibitory receptor that has been previously reported to be
induced by IL-3 [12]. We thus confirmed IL-3-induced expression
of NKp44 on pDCs and showed that also DAP12/KARAP
mRNA, the NKp44-associated signalling adaptor protein, is
regularly expressed by pDCs (Figure 1D, left panel). As previously
reported [12], the association of IL-3 with CpG prevented the
expression of NKp44 on pDCs. In addition, we now show that the
expression of NKp44 induced by IL-3 can also be prevented by
the presence of exogenous IFNa (Figure 1B, bottom panel).
LAIR-1 engagement on pDCs induces inhibition of IFNa
production
We next investigated the functional effects of LAIR-1 triggering
in pDCs. First, we analyzed the effect of LAIR-1 cross-linking on
the production of IFNa by CpG ODN-activated pDCs. Our data
indicate that the engagement of LAIR-1 significantly inhibited
IFNa secretion in response to CpG stimulation (Figure 2A).
Moreover, since the production of IFNa has been described to
play a pivotal role in systemic lupus erithemathosus (SLE) as well
as in the pathogenesis of other autoimmune disease, we
investigated the effect of LAIR-1 cross-linking on pDCs stimulated
with DNA/anti-DNA immunocomplexes. In these experiments,
pDCs were stimulated with DNA from apoptotic cells in the
presence of serum from SLE patients. This culture system has been
previously shown to induce IFNa release by pDCs [23]. As shown
in figure 2B, LAIR-1 cross-linking effectively inhibited IFNa
production by pDCs in response to SLE serum-derived anti-DNA
immune complexes. NKp44 was similarly able to inhibit IFNa
production by pDCs stimulated by SLE anti-DNA immunocom-
plexes and, remarkably, consistently synergized with LAIR-1 for
inhibiting IFNa release.
LAIR-1 and NKp44 expression in peripheral tissue pDCs
NKp44 has been reported to be expressed in a subset of tonsil
pDCs and its expression was associated with the presence of IL-3
released by CD8
+ memory T cells found in close proximity to
pDCs [12]. In addition to inflamed tonsils (figure 3B), we have
now extended the analysis also to non-reactive lymph nodes and
found a similar expression of NKp44 in lymph node pDCs as well
as in tumor-associated pDCs (Figure 3C,D,E). Tumor-associated
pDCs were analyzed in non-small-cell-lung cancer (NSCLC), in
renal cell carcinomas and melanomas (Figure 3D,E) and
expression of NKp44 was detected in all tumors analyzed. These
latter results will deserve further investigation since the ligand of
NKp44, although still elusive, is known to be expressed on several
cancer cell lines and might therefore impact on pDC function
during the in vivo anti-tumor immune response. Moreover,
different from peripheral blood pDCs, both lymph node and
tumor-associated pDCs showed a discrete level of activation,
assessed as surface CD83 expression (Figure 3E,F).
Since NKp44 expression on secondary lymphoid organs pDCs
is assumed to be related to locoregional IL-3 production, we
expected to detect, on the basis of our in vitro observations, a
decreased expression of LAIR-1 in lymph node pDCs. However,
as shown in figure 3C, the expression of LAIR-1 was similar in
peripheral blood and autologous lymph node pDCs. Of note, the
expression of BDCA-2, which is also reported to be down-
regulated in the presence of IL-3 [5,24], was comparable to that
observed on autologous peripheral blood pDCs.
Plasmacytoid DCs and Natural Killer cells share the same
NKp44 protein sequence
In line with the reported inhibitory role of NKp44 in pDCs, we
have shown that this receptor displays inhibitory activity also when
pDCs are stimulated by anti-DNA immunocomplexes (Figure 2B),
a model that more closely resembles the triggering of pDCs during
autoimmune diseases. NKp44 has been initially identified as an
activating receptor in NK cells and the molecular basis for this
paradoxic behaviour in these two distinct leukocyte subsets has not
yet been dissected. We therefore assessed whether the opposite
functional outcomes of NKp44 triggering in NK cells and pDCs
could be related to differences in the intracytoplasmic tail of the
receptor. Thus, we amplified NKp44 cDNA from IL-3-treated
healthy donor pDCs as well as from lymph node pDCs; analysis of
nucleotide sequences demonstrated a complete identity with
NKp44 molecule expressed on NK cells.
In addition, we analyzed nucleotide sequences of DAP12, the
NKp44-associated adaptor protein, in pDCs and confirmed also in
this case a complete identity with DAP12 expressed in NK cells.
pDCs isolated from systemic lupus erithematosus
patients express lower levels of LAIR-1
It has been shown that systemic lupus erithematosus (SLE)
patients exhibit elevated IFNa serum levels, which correlate with
both disease activity and severity [25,26]. Accordingly, activated
pDCs, as a major source of IFNa, are possibly involved in the
pathogenesis of SLE. Since we observed that in vitro pDC
activation results in a decreased expression of LAIR-1, we
investigated whether the expression of LAIR-1 was decreased on
pDCs derived from SLE patients. To this aim, we collected
peripheral blood of pediatric SLE patients and age-matched
healthy donors and investigated the levels of LAIR-1 expression on
pDCs. We found that the levels of LAIR-1 expression on pDCs
isolated from SLE patients were significantly lower than those
detectable on pDCs from healthy donors (Figure 4). On the other
LAIR-1 Engagement on pDCs Inhibits IFN,alpha. Release
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e15080Figure 1. Expression of LAIR-1 and NKp44 on peripheral blood pDCs from healthy donors. Expression of LAIR-1 was assessed on pDCs
from healthy donors PBMCs (A) and on purified pDCs (B) following culture in the presence of IL-3 (20 ng/ml), CpG (5 mg/ml) or IFNa (1000 U/ml) for
48 hours. (B): Dotted lines depict unstimulated cells; bold lines depict cells cultured as indicated. Values represent expression Geo-MFI. All
experiments related to the analysis of LAIR-1 expression on pDCs cultured with the indicated stimuli for 24 and 48 hours are summarized in (C).
Values depict Geo-MFI of positive cells/Geo-MFI of Ig isotype-matched control stained cells. (D): Analysis of LAIR-1, NKp44 and DAP12 mRNA
expression on human pDCs. Polyclonal NK cell lines, pDCs and pDCs cultured 48 h with IL-3 were analyzed by RT-PCR for LAIR-1, NKp44 and DAP12
expression (see Materials and Methods).
doi:10.1371/journal.pone.0015080.g001
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display a slight but consistent expression of NKp44, which was
rarely detectable in healthy donors.
Discussion
pDCs are considered as the most potent ‘‘natural IFN-
producing cells’’ [27] and, through production of this cytokine,
they might activate multiple effector mechanisms of the immune
system, including T cells, B cells and NK cells [3]. IFNa is a
pivotal cytokine in antiviral immunity and is also associated with
different autoimmune disorders such as lupus erythematosus,
psoriasis, dermatomyositis and Sjogren’s syndrome [1,2,28]. In
SLE, pDCs might become chronically activated by antigen-
antibody complexes containing RNA and DNA via TLR7 and 9,
respectively [23]. Notably, IFNa levels are increased in sera of
SLE patients and it has been postulated that this cytokine might be
involved in myeloid DC activation during SLE disease [29]. As a
consequence, IFNa producing pDCs have been suggested to be
implicated in the pathogenesis of lupus disease [26]. Nevertheless,
despite the relevance of IFNa in both normal and pathological
immune response, the molecular mechanisms for the negative
regulation of pDCs are not yet fully elucidated. Recently, novel
pDC receptors able to modulate IFNa release have been
described, such as NKp44 and IRp60 [11,12]. NKp44 and
IRp60 had been previously characterized as, respectively,
activating and inhibitory receptors in other immune cell types
[10,13,14]. Paradoxically, NKp44 acts on pDCs decreasing the
release of IFNa in response to TLR-agonists, whereas IRp60
triggering results in an increase of IFNa production.
Here we show, for the first time, that LAIR-1 is expressed on
pDCs and that its expression decreases along differentiation of
pDCs in the presence of IL-3, as well as upon stimulation by CpG
ODN, suggesting that pDCs exhibit decreased expression of LAIR-
1 after activation. This confirms data reported in other immune cell
types. Indeed, LAIR-1 expression was found to decrease in B
lymphocytes upon cell activation in vitro [30]. Naı ¨ve B cells express
high levels of LAIR-1 but the expression is absent in 50% of
memory B cells and in plasma cells [30]. In T cells, LAIR-1
expression is high on naı ¨ve cells but lower and more heterogeneous
on memory cells [31]. Thus, in several types of immune cells, a high
cell surface expression of LAIR-1 is associated with a less
differentiated phenotype, while LAIR-1 expression on memory
and terminally differentiated cells is more heterogeneous.
We have demonstrated that mAb-mediated crosslinking of
LAIR-1 sharply inhibits the release of IFNa by pDC stimulated by
TLR ligands. Therefore, the strong inhibitory function previously
assigned to LAIR-1 in studies focused on other leukocyte subsets,
has been confirmed in the present analysis of pDC function.
Interestingly, exposure of pDCs to exogenous IL-3 results in two
opposite effects: down-modulation of LAIR-1 and induction of
NKp44 expression. Since triggering of both NKp44 and LAIR-1
on pDCs results in the inhibition of IFNa release upon TLR
ligand stimulation, a cytokine-regulated coordinated function of
LAIR-1 and NKp44 can be envisaged.
We also demonstrated that the presence of IFNa decreases the
expression of LAIR-1 on pDCs and concomitantly inhibits IL-3-
induced expression of NKp44. Similarly, also IRp60 expression on
pDCs was recently described to be down-regulated by TLR
ligands and this effect was associated to the release of IFNa by
pDCs. Thus, CpG might also induce a decreased expression of
both LAIR-1 and NKp44 via the release of IFNa. However, while
IFNa can be envisioned as a mechanism of negative feedback, the
functional significance of the down-regulation of two pDC
inhibitory receptors by IFNa remains uncertain.
NKp44 expression on pDCs has been previously associated to
the presence of IL-3 released by memory CD8
+ T cells, found in
close proximity to pDCs in tonsils [12]. Nevertheless, we now
show that the expression of NKp44 in pDCs of secondary
lymphoid organs, such as lymph nodes and tonsils, is not coupled
to a decreased expression of LAIR-1. This may suggest that in
secondary lymphoid organs, besides IL-3, other factors might
induce the expression of NKp44 on pDCs without affecting the
levels of LAIR-1 expression.
Given the potential role of IFNa in SLE pathogenesis, we
assessed whether cross-linking of LAIR-1 or NKp44 might affect
IFNa production by pDCs stimulated not only with CpG but also
with DNA/SLE anti-DNA immune complexes. Our results
demonstrate that cross-linking of LAIR-1 effectively inhibited
IFNa production by pDCs in response to DNA immunocom-
plexes. Remarkably, also NKp44 effectively inhibited IFNa
production by pDCs in response to these stimuli and consistently
synergized with LAIR-1 to provide optimal inhibitory function.
Having confirmed the inhibitory activity of NKp44 also in pDCs
stimulated with DNA immunocomplexes, we wondered whether
NKp44 molecule expressed by pDCs might differ from that
expressed by NK cells (where the same receptor activates NK cell
functions), hypothesizing, for instance, differences in its intracyto-
Figure 2. LAIR-1 triggering on pDCs induces inhibition of IFNa
production. LAIR-1 cross-linking inhibits IFNa production by pDCs
activated with either CpG (A) or DNA immunocomplexes (B). pDCs were
cultured for 18 h in the presence of IL-3, incubated with the indicated
mAbs or isotype-matched mAbs (Ctrl mAb) and then cultured in F(ab)2
goat anti-mouse IgG antibody-coated plates in the presence of CpG or
DNA immunocomplexes. IFNa production was assessed by ELISA in
culture supernatants. Graphs represent mean values +/2 SEM of three
independent experiments. ** p,0.01; * p,0.05.
doi:10.1371/journal.pone.0015080.g002
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complete identity of both NKp44 and the related adaptor protein
DAP12 with the same molecules expressed on NK cells. Thus, the
signalling mechanisms ruling this contrasting behaviour in the two
cell types remains yet unknown. One possibility relates to alternative
signalling delivered via DAP12, which contains immunoreceptor
tyrosine-based activating motif (ITAM), which recruits protein
tyrosine kinases [32]. As a matter of fact, in some instances, it has
been reported that ITAMs can recruit tyrosine phosphatases instead
of tyrosine kinases and therefore mediate inhibition [12,15,33]. On
the other hand,another explanation may reside inNKp44-mediated
release of yet unidentified cytokines able to inhibit IFNa production.
We also found that pDCs from SLE patients express lower
amounts of LAIR-1 as compared to age-matched healthy donors.
The impaired expression in SLE patients most likely reflects the
activation of pDCs, which has been suggested to occur in these
Figure 3. Expression of LAIR-1 and NKp44 on peripheral tissue pDCs. pDCs were identified in different tissues as BDCA-2
+ ILT3
+ positive cells
(A). LAIR-1 and NKp44 expression was evaluated in tonsils (B), lymph nodes (C and E) and in different malignant tumors (D and E). pDCs activation in
lymph nodes and in NSCLC was assessed as CD83 expression (E and F). The horizontal bars within dot-plots of panels C, D, F represent negative
controls with isotype-matched irrelevant mAbs. Data shown are representative of at least three independent experiments analyzing pDCs from
different patient tissues.
doi:10.1371/journal.pone.0015080.g003
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However, in the same SLE patients cohort, also lymphocytes
displayed lower levels of LAIR-1 (not shown), which might be
similarly related to their in vivo activation [31]. Nevertheless,
another intriguing scenario may envisage an inherited deficiency
of one or more inhibitory receptors that might be involved in the
pathogenesis of the autoimmune disease. However, this latter
hypothesis contrasts with the slight but consistent expression of
NKp44 observed on SLE PB pDCs, which also points to an
activation status of pDCs in SLE patients. Whatever the case, a
persistently impaired expression of pDC inhibitory receptors, such
as LAIR-1 or BDCA-2 [24], might contribute to the maintenance
of elevated IFNa levels and therefore to the pathologic immune
response.
In conclusion, we have described the expression of the immune
inhibitory receptor LAIR-1 on pDCs and showed that, in a
coordinated fashion with NKp44, it is able to control the release of
IFNa in response to TLR ligands, including anti-DNA immuno
complexes. In addition, we extended previous knowledge about
NKp44 function in pDCs of peripheral blood and tissues. A
deeper understanding of the mechanisms ruling type I IFN
production and, more specifically, of pDC functional receptors,
will be fundamental for planning new immune interventions for
controlling autoimmune, viral and neoplastic diseases.
Materials and Methods
Ethics Statement
This study was approved by the Ethics Committee of Istituto
Nazionale per la Ricerca sul Cancro, Genoa (in order to obtain
cancer patient blood and tissues) and of Istituto G.Gaslini, Genoa
(in order to obtain peripheral blood sera and cells of SLE patients).
All patients gave written informed consent according to the
Declaration of Helsinki.
Figure 4. Expression of LAIR-1 and NKp44 on pDCs from SLE patients. PBMC samples were isolated from SLE patients and age matched
healthy donors and the levels LAIR-1 and NKp44 expression on pDCs were investigated. A representative experiment is shown in panel A. The
horizontal bars within the dot-plot depict negative controls with isotype-matched irrelevant mAbs. Results from different independent experiments
are summarized in B. Geo-MFI index was used to compare the levels of LAIR-1 and NKp44 expression on pDCs and calculated as: Geo-MFI of positive
cells/Geo-MFI of isotype staining cells.
doi:10.1371/journal.pone.0015080.g004
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The following mAbs were employed for pDC identification and
analysis: allophycocyanin- or FITC-conjugated anti-BDCA-2
(clone AC144) (Miltenyi Biotec, Bergish Gladbach, Germany),
anti-LAIR-1 (clone 1F1) and anti-NKp44 (clone Z231 and KS38)
produced in our laboratory, PC5-conjugated anti-ILT3 (clone
ZM3.8) and PE-conjugated anti-CD83 (clone HB15A) (Beckman
Coulter, Immunotech, Marseille, Cedex, France).
For analysis of pDCs in secondary lymphoid organ and tumors,
cells were labeled with anti-ILT-3 and BDCA-2 mAbs and
analysis was performed on ILT3
+ and BDCA-2
+ cells. For indirect
immunofluorescence staining, the relevant mAb was added and
incubated for 30 min at 4uC. After extensive washing, FITC- or
PE-conjugated isotype-specific goat anti-mouse mAbs (Southern
Biotechnology Associates, Birmingham, AL) were added and
incubated for 30 min at 4uC. Negative controls included directly
labeled or unlabeled isotype-matched irrelevant mAbs.
Analysis were carried out by FACSCanto II flow cytometer
(Becton Dickinson, Mountain View, CA). Data analysis was
performed using Flowjo software 7.5.3 (Tree Star).
pDC isolation, culture and tissue processing
Human PBMCs were prepared by Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden) density gradient centrifugation of buffy coats
from normal donors (Blood Center, A.O.U., Messina) or SLE
patient whole blood and corresponding healthy controls (Istituto
G. Gaslini, Genoa). pDCs were obtained from PBMCs by using
MACS magnetic labelling system (Miltenyi Biotec, Bergish
Gladbach, Germany). Briefly, pDCs were purified by negative
selection using pDC isolation kit and MACS LD columns
(Miltenyi Biotec). Purity was at least 97%. Purified pDCs were
cultured in RPMI 1640 (Euroclone, Milan, Italy), supplemented
with 10% fetal bovine serum (Euroclone, Milan, Italy), penicillin
(60 mg/ml), streptomycin (100 mg/ml), L-glutamine (2 mM) and
IL-3 (20 ng/mL) (all from R&D Systems, Minneapolis, MN). For
pDCs stimulation, 5 mg/mL CpG ODN-A (TIB Molbiol, Genoa,
Italy) or IFNa (1000 U/ml) (Schering Plough) were added to
cultures at the indicated time point (24 or 48 hours). Secondary
lymphoid organs and tumor tissue were processed as previously
described [34,35]. Briefly, secondary lymphoid organs were
mechanically dissociated and then filtered through a 100 m nylon
cell strainer (BD Labware, Mountain View, CA) to exclude
undissociated fragments. Debris and dead cells were eliminated
using a Ficoll-Hypaque discontinuous gradient. Tumor tissues
were processed by mechanical dissociation followed by enzymatic
digestion. the down-regulation of IRp60 on pDCs by.
IFNa detection following stimulation and receptor cross-
linking
For receptor cross-linking experiments, pDCs were labelled with
saturating amount of the indicated mAbs and then cultured in 96-
well plates coatedwith F(ab)2 goat antimouseIgGantibody(10 mg/
mL; Southern Biotechnology Associates, Birmingham, AL).
5610
4 pDCs/well were cultured with 2,5% human sera, penicillin
(60 mg/ml), streptomycin (100 mg/ml), L-glutamine (2 mM), IL-3
(20 ng/mg) and CpG ODN-A (5 mg/ml; Tib MolBiol, Genoa) in a
final volume of 0,1 ml. After 48 h culture supernatants were
harvested for cytokine analysis. Alternatively, for stimulation by
DNA immunocomplexes, 5610
4 pDCs were cultured in RPMI
supplemented with 5610
4 c-irradiated U937 cells, in the presence
of 13% SLE serum, as previously described [23].
For NKp44 cross-linking experiments pDCs were previously
cultured for 18 h in the presence of IL-3 (20 ng/mL; R&D
Systems, Minneapolis, MN) in order to induce NKp44 expression.
The levels of IFNa in culture supernatants were determined by an
ELISA kit according to manufactures’instructions (R&D System).
RT-PCR analysis and sequencing
Total RNA was extracted from polyclonal NK cell populations,
pDC and pDC cultured for 48 h in the presence of IL-3 using
RNAeasy Micro Kit (Qiagen, Hilden, Germany). Oligo (dT)-
primed cDNA was prepared by standard technique using Tran-
scriptor (Roche, Monza, Italy). PCR amplifications were per-
formed with the following primers: b-actin up ACTCCATCAT-
GAAGTGTGACG; b-actin dw CATACTCCTGCTTGCTGA-
TCC; LAIR-1 ORF up 59 GTATGGGGTCAGTGTCTGG;
LAIR-1 ORF dw 59 CATTGGTGCGCCTCAGGC; NKp44
ORF up 59 CCACGAGCGCACAGGAAAAGG; NKp44 ORF
dw 59 TCACAAAGTGTGTTCATCATCATCATCGCTTAT-
CTTAGTCC; DAP12 up 59 TCATGGGGGGACTTGAACC;
DAP12 dw 59 GATTCGGGCTCATTTGTAATAC. Amplifica-
tions were performed utilizing Platinum TAQ (Invitrogen,
Carlsbad, CA) for 30 cycles (30 sec. at 95uC, 30 sec. at 58uC,
1 min. at 68uC) except for NKp44 for which the annealing
temperature was 65uC. PCR products (249 bp fragment for b-
actin, 916 bp for LAIR-1, 857 bp for NKp44 and 353 bp for
DAP12) were run on a 0.8% agarose gel and visualized by
ethidium bromide staining. LAIR-1, NKp44 and DAP12 PCR
products amplified from pDC were subcloned in pcDNA3.1/V5-
His TOPO vector (Invitrogen, Carlsbad, CA). DNA sequencing
was performed using BigDye Terminator Cycle Sequencing Kit
and a 377 Applied Biosystems Automatic Sequencer (Perkin
Elmer-Applied Biosystems).
Statistical analysis
The significance of difference between groups was calculated by
t-test using GraphPad Prism 4.0 software (GraphPad Software,
San Diego, CA). P values less than or equal to 0,05 were
considered significant.
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